Author details

Full Name

Mark K Louder

Affiliation

ORCID

Career Start Year

1994

Papers

110

H Index

Expertise

CM4AI Collaborator

PMID	Paper Title	Journal Title	Published Year
37098956	Diverse Murine Vaccinations Reveal Distinct Antibody Classes to Target Fusion Peptide and Variation in Peptide Length to Improve HIV Neutralization.		2023
37989731	Antibody-directed evolution reveals a mechanism for enhanced neutralization at the HIV-1 fusion peptide site.		2023
37886518	Human CD4-Binding Site Antibody Elicited by Polyvalent DNA Prime-Protein Boost Vaccine Neutralizes Cross-Clade Tier-2-HIV Strains.		2023
37345226	Improved pharmacokinetics of HIV-neutralizing VRC01-class antibodies achieved by reduction of net positive charge on variable domain.		2023
37436900	Improved HIV-1 neutralization breadth and potency of V2-apex antibodies by in silico design.		2023
36729903	Bispecific antibody CAP256.J3LS targets V2-apex and CD4-binding sites with high breadth and potency.	MAbs	2023
35319830	Development of Neutralization Breadth against Diverse HIV-1 by Increasing Ab-Ag Interface on V2.	Advanced Science	2022
36284200	Engineering of HIV-1 neutralizing antibody CAP256V2LS for manufacturability and improved half life.	Scientific Reports	2022
35413243	Structural basis for llama nanobody recognition and neutralization of HIV-1 at the CD4-binding site.	Structure	2022
34753907	Extended antibody-framework-to-antigen distance observed exclusively with broad HIV-1-neutralizing antibodies recognizing glycan-dense surfaces.	Nat Commun	2021
33453152	Vaccination induces maturation in a mouse model of diverse unmutated VRC01-class precursors to HIV-neutralizing antibodies with >50% breadth.	Immunity	2021
34328065	A matrix of structure-based designs yields improved VRC01-class antibodies for HIV-1 therapy and prevention.	mAbs	2021
33649208	Mutational fitness landscapes reveal genetic and structural improvement pathways for a vaccine-elicited HIV-1 broadly neutralizing antibody.	Proc Natl Acad Sci U S A	2021
34407396	Rapid selection of HIV envelopes that bind to neutralizing antibody B cell lineage members with functional improbable mutations.	Cell Reports	2021
34731616	Structural basis of glycan276-dependent recognition by HIV-1 broadly neutralizing antibodies.	Cell Rep	2021
32722908	Evaluation of the mRNA-1273 Vaccine against SARS-CoV-2 in Nonhuman Primates.	N Engl J Med	2020
32268107	Structure of Super-Potent Antibody CAP256-VRC26.25 in Complex with HIV-1 Envelope Reveals a Combined Mode of Trimer-Apex Recognition.	Cell Rep	2020
32130953	VRC34-Antibody Lineage Development Reveals How a Required Rare Mutation Shapes the Maturation of a Broad HIV-Neutralizing Lineage.	Cell Host Microbe	2020
32756549	SARS-CoV-2 mRNA vaccine design enabled by prototype pathogen preparedness.	Nature	2020
32577634	SARS-CoV-2 mRNA Vaccine Development Enabled by Prototype Pathogen Preparedness.	bioRxiv	2020
33121334	Removal of variable domain -linked glycosylation as a means to improve the homogeneity of HIV-1 broadly neutralizing antibodies.	mAbs	2020
31348886	Antibody Lineages with Vaccine-Induced Antigen-Binding Hotspots Develop Broad HIV Neutralization.	Cell	2019
31732167	Vaccination with Glycan-Modified HIV NFL Envelope Trimer-Liposomes Elicits Broadly Neutralizing Antibodies to Multiple Sites of Vulnerability.	Immunity	2019
30604750	Lattice engineering enables definition of molecular features allowing for potent small-molecule inhibition of HIV-1 entry.	Nature Communications	2019
30471922	Structural Survey of Broadly Neutralizing Antibodies Targeting the HIV-1 Env Trimer Delineates Epitope Categories and Characteristics of Recognition.	Structure	2019
30876875	Longitudinal Analysis Reveals Early Development of Three MPER-Directed Neutralizing Antibody Lineages from an HIV-1-Infected Individual.	Immunity	2019
30760721	Improvement of antibody functionality by structure-guided paratope engraftment.	Nature Communications	2019
31263112	Difficult-to-neutralize global HIV-1 isolates are neutralized by antibodies targeting open envelope conformations.	Nature Communications	2019
29548671	A Neutralizing Antibody Recognizing Primarily N-Linked Glycan Targets the Silent Face of the HIV Envelope.	Immunity	2018
29867235	Epitope-based vaccine design yields fusion peptide-directed antibodies that neutralize diverse strains of HIV-1.	Nat Med	2018
29491415	Rational design of a trispecific antibody targeting the HIV-1 Env with elevated anti-viral activity.	Nature Communications	2018
29444432	Surface-Matrix Screening Identifies Semi-specific Interactions that Improve Potency of a Near Pan-reactive HIV-1-Neutralizing Antibody.	Cell Rep	2018
28052137	Mapping Polyclonal HIV-1 Antibody Responses via Next-Generation Neutralization Fingerprinting.	PLoS Pathog	2017
28825711	Crystal structures of trimeric HIV envelope with entry inhibitors BMS-378806 and BMS-626529.	Nature Chemical Biology	2017
28445724	Quantification of the Impact of the HIV-1-Glycan Shield on Antibody Elicitation.	Cell Rep	2017
28931639	Trispecific broadly neutralizing HIV antibodies mediate potent SHIV protection in macaques.	Science	2017
28878010	Broadly neutralizing antibodies targeting the HIV-1 envelope V2 apex confer protection against a clade C SHIV challenge.	Science Translational Medicine	2017
28783671	Potent and broad HIV-neutralizing antibodies in memory B cells and plasma.	Science immunology	2017
28514685	Virus-like Particles Identify an HIV V1V2 Apex-Binding Neutralizing Antibody that Lacks a Protruding Loop.	Immunity	2017
29170366	Initiation of HIV neutralizing B cell lineages with sequential envelope immunizations.	Nature Communications	2017
28298421	Mimicry of an HIV broadly neutralizing antibody epitope with a synthetic glycopeptide.	Science Translational Medicine	2017
28298420	Staged induction of HIV-1 glycan-dependent broadly neutralizing antibodies.	Science Translational Medicine	2017
27581986	Structure of an N276-Dependent HIV-1 Neutralizing Antibody Targeting a Rare V5 Glycan Hole Adjacent to the CD4 Binding Site.	Journal of Virology	2016
27053554	Optimization of the Solubility of HIV-1-Neutralizing Antibody 10E8 through Somatic Variation and Structure-Based Design.	J Virol	2016
27174988	Fusion peptide of HIV-1 as a site of vulnerability to neutralizing antibody.	Science	2016
26949186	Maturation Pathway from Germline to Broad HIV-1 Neutralizer of a CD4-Mimic Antibody.	Cell	2016
27028935	Optimal Combinations of Broadly Neutralizing Antibodies for Prevention and Treatment of HIV-1 Clade C Infection.	PLoS Pathogens	2016
26689967	Structures of HIV-1 Env V1V2 with broadly neutralizing antibodies reveal commonalities that enable vaccine design.	Nat Struct Mol Biol	2016
27851912	Identification of a CD4-Binding-Site Antibody to HIV that Evolved Near-Pan Neutralization Breadth.	Immunity	2016
27654288	Multiple Antibody Lineages in One Donor Target the Glycan-V3 Supersite of the HIV-1 Envelope Glycoprotein and Display a Preference for Quaternary Binding.	J Virol	2016